Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ivan Foeldvari & Harry Petrushkin. (2023) How should we approach management of childhood onset chronic anterior uveitis refractory to adalimumab?. Expert Review of Clinical Immunology 0:0, pages 1-10.
Read now
Read now
Rolando Cimaz, Gabriella Maioli & Giulia Calabrese. (2020) Current and emerging biologics for the treatment of juvenile idiopathic arthritis. Expert Opinion on Biological Therapy 20:7, pages 725-740.
Read now
Read now
Ilaria Maccora, Maria Pia dell’Anna, Alfredo Vannacci & Gabriele Simonini. (2020) Safety evaluations of adalimumab for childhood chronic rheumatic diseases. Expert Opinion on Drug Safety 19:6, pages 661-671.
Read now
Read now
Achille Marino, Teresa Giani & Rolando Cimaz. (2019) Risks associated with use of TNF inhibitors in children with rheumatic diseases. Expert Review of Clinical Immunology 15:2, pages 189-198.
Read now
Read now
Sunil Dogra & Rahul Mahajan. (2018) Biologics in pediatric psoriasis – efficacy and safety. Expert Opinion on Drug Safety 17:1, pages 9-16.
Read now
Read now
Articles from other publishers (30)
Gerd Horneff. (2022) Innovationen in der Behandlung der juvenilen idiopathischen Arthritis. Pädiatrie up2date 17:04, pages 337-353.
Crossref
Crossref
Yaseen Hussain & Haroon Khan. 2022. Encyclopedia of Infection and Immunity. Encyclopedia of Infection and Immunity
726
740
.
Cécile Dumaine, Sara Bekkar, Alexandre Belot, Natalia Cabrera, Salma Malik, Annette von Scheven, Aurelia Carbasse, Andreas Woerner, Carine Wouters, Kenza Bouayed, Pascal Pillet, Silke Schroeder, Michael Hofer & Véronique Hentgen. (2021) Évènements indésirables infectieux chez des enfants atteints d’arthrite juvénile idiopathique et traités en vie réelle par biothérapies : données issues de la JIR cohorte. Revue du Rhumatisme 88:6, pages 443-449.
Crossref
Crossref
Natalie J. Shiff & Timothy Beukelman. (2021) Pharmacosurveillance in Juvenile Idiopathic Arthritis. Rheumatic Disease Clinics of North America 47:4, pages 643-653.
Crossref
Crossref
Franz Thiele, Ariane Klein, Daniel Windschall, Anton Hospach, Ivan Foeldvari, Kirsten Minden, Frank Weller-Heinemann & Gerd Horneff. (2021) Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatology International 41:4, pages 751-762.
Crossref
Crossref
Jaqueline Cristina da Silveira Xavier e Castro, Stephanie Ferreira Botelho, Maria Auxiliadora Parreiras Martins, Liliana Batista Vieira & Adriano Max Moreira Reis. (2021) New drugs registered in Brazil from 2003 to 2013: analysis from the perspective of child health. Brazilian Journal of Pharmaceutical Sciences 57.
Crossref
Crossref
Sibel Balcı, İlksen Demir, Mahir Serbes, Dilek Doğruel, Derya Ufuk Altıntaş & Rabia Miray Kışla Ekinci. (2020) Retrospective analyzes of adverse events during biologic agents in children with juvenile idiopathic arthritis from a single center in Turkey. Rheumatology 58:6, pages 367-374.
Crossref
Crossref
Hermine I. Brunner, Kabita Nanda, Mary Toth, Ivan Foeldvari, John Bohnsack, Diana Milojevic, C. Egla Rabinovich, Daniel J. Kingsbury, Katherine Marzan, Elizabeth Chalom, Gerd Horneff, Rolf‐Michael Kuester, Jason A. Dare, Maria Trachana, Lawrence K. Jung, Judyann Olson, Kirsten Minden, Pierre Quartier, Mareike Bereswill, Jasmina Kalabic, Hartmut Kupper, Daniel J. Lovell, Alberto Martini & Nicolino Ruperto. (2020) Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results. Arthritis Care & Research 72:10, pages 1420-1430.
Crossref
Crossref
Sandra Rodríguez, Andrés Muñoz, Rosa-Helena Bustos & Diego Jaimes. (2020) Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview. Biomedicines 8:9, pages 303.
Crossref
Crossref
Ethan S. Sen & A.V. Ramanan. (2020) Juvenile idiopathic arthritis-associated uveitis. Clinical Immunology 211, pages 108322.
Crossref
Crossref
Cécile Dumaine, Sara Bekkar, Alexandre Belot, Natalia Cabrera, Salma Malik, Annette von Scheven, Aurelia Carbasse, Andreas Woerner, Carine Wouters, Kenza Bouayed, Pascal Pillet, Silke Schroeder, Michael Hofer & Véronique Hentgen. (2020) Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte. Joint Bone Spine 87:1, pages 49-55.
Crossref
Crossref
I. W. FongI. W. Fong. 2020. Current Trends and Concerns in Infectious Diseases. Current Trends and Concerns in Infectious Diseases
131
163
.
Arnold Nagy, Péter Mátrai, Péter Hegyi, Hussain Alizadeh, Judit Bajor, László Czopf, Zoltán Gyöngyi, Zoltán Kiss, Katalin Márta, Mária Simon, Ágnes Lilla Szilágyi, Gábor Veres & Bernadett Mosdósi. (2019) The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: a meta-analysis. Pediatric Rheumatology 17:1.
Crossref
Crossref
Sibel BalcıRabia Miray Kışla EkinciMahir SerbesDilek DoğruelDerya Ufuk AltıntaşMustafa Yılmaz. (2019) Etanercept for the Treatment of Chronic Arthritis Related to Chronic Granulomatous Disease: A Case. Pediatric Allergy, Immunology, and Pulmonology 32:3, pages 131-134.
Crossref
Crossref
Gerd Horneff. (2019) Neue Substanzen zur Therapie der juvenilen idiopathischen ArthritisNew drugs for treatment of juvenile idiopathic arthritis. Zeitschrift für Rheumatologie 78:7, pages 587-598.
Crossref
Crossref
L. Cavazzana, M. Fornili, G. Filocamo, C. Agostoni, F. Auxilia & S. Castaldi. (2018) Hospital clinical pathways for children affected by juvenile idiopathic arthritis. Italian Journal of Pediatrics 44:1.
Crossref
Crossref
M. Bielak, E. Husmann, N. Weyandt, J.-P. Haas, B. Hügle, G. Horneff, U. Neudorf, T. Lutz, E. Lilienthal, T. Kallinich, K. Tenbrock, R. Berendes, T. Niehues, H. Wittkowski, E. Weißbarth-Riedel, G. Heubner, P. Oommen, J. Klotsche, Dirk Foell & E. Lainka. (2018) IL-6 blockade in systemic juvenile idiopathic arthritis – achievement of inactive disease and remission (data from the German AID-registry). Pediatric Rheumatology 16:1.
Crossref
Crossref
Surabhi S. Vinod, Annelle B. Reed, Jamelle Maxwell, Randy Q. Cron & Matthew L. Stoll. (2018) Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year. Pediatric Rheumatology 16:1.
Crossref
Crossref
Jeong Yun Choi, Jee Eun Chung, Ji Hyun Park, Yoon Sook Cho, Yong Woo Jung & Soo An Choi. (2018) Surveillance of adverse drug events associated with etanercept prescribed for juvenile idiopathic arthritis in a single center up to 9-years: A retrospective observational study. PLOS ONE 13:11, pages e0204573.
Crossref
Crossref
Gerd Horneff, Marieke M.B. Seyger, Dilek Arikan, Jasmina Kalabic, Jaclyn K. Anderson, Andreas Lazar, David A. Williams, Chen Wang, Rita Tarzynski-Potempa & Jeffrey S. Hyams. (2018) Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease. The Journal of Pediatrics 201, pages 166-175.e3.
Crossref
Crossref
Iris Deitch, Radgonde Amer, Oren Tomkins-Netzer, Zohar Habot-Wilner, Ronit Friling, Ron Neumann & Michal Kramer. (2018) The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies. Graefe's Archive for Clinical and Experimental Ophthalmology 256:4, pages 801-808.
Crossref
Crossref
Amro Ali, Cyril Rosenfeld, Eric Rosenberg, Sansar Sharma & Thaddeus L. Wandel. (2017) Chronic Uveitis Following Neodymium-Doped Yttrium Aluminum Garnet Laser Peripheral Iridotomy. Journal of Glaucoma 26:10, pages e229-e231.
Crossref
Crossref
Rolando Cimaz, Achille Marino & Alberto Martini. (2017) How I treat juvenile idiopathic arthritis: A state of the art review. Autoimmunity Reviews 16:10, pages 1008-1015.
Crossref
Crossref
Sara MuriasLorena MagallaresFatima Albizuri, Dora Pascual-SalcedoErwin Dreesen & Denis Mulleman. (2017) Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics. Therapeutic Drug Monitoring 39:4, pages 370-378.
Crossref
Crossref
Jorg van Loosdregt, Femke van Wijk, Berent Prakken & Bas Vastert. (2017) Update on research and clinical translation on specific clinical areas from biology to bedside: Unpacking the mysteries of juvenile idiopathic arthritis pathogenesis. Best Practice & Research Clinical Rheumatology 31:4, pages 460-475.
Crossref
Crossref
Ethan S. Sen & A.V. Ramanan. (2017) Juvenile idiopathic arthritis-associated uveitis. Best Practice & Research Clinical Rheumatology 31:4, pages 517-534.
Crossref
Crossref
Al-Mayouf SM. (2017) Biologic therapy-Related demyelinating peripheral neuropathy in a child with Juvenile Idiopathic Arthritis. Archives of Pharmacy and Pharmaceutical Sciences 2:1, pages 020-022.
Crossref
Crossref
Sarah L. N. Clarke, Ethan S. Sen & Athimalaipet V. Ramanan. (2016) Juvenile idiopathic arthritis-associated uveitis. Pediatric Rheumatology 14:1.
Crossref
Crossref
Sarah E. Henrickson, Melanie A. Ruffner & Mildred Kwan. (2016) Unintended Immunological Consequences of Biologic Therapy. Current Allergy and Asthma Reports 16:6.
Crossref
Crossref
Ellen Mosley. (2015) Practical guide to treating children with juvenile idiopathic arthritis. Paediatrics and Child Health 25:12, pages 587-591.
Crossref
Crossref